A mid-stage clinical study of RAP-219 is delivering striking results for adults with drug-resistant focal epilepsy, a group that often cycles through multiple medicines with limited relief. As first reported by New Atlas, investigators observed large drops in seizure activity, including a median 77.8% reduction in clinical seizures over eight weeks and seizure-freedom for nearly a quarter of participants—rare outcomes in such a hard-to-treat population.
Who’s behind the progress
The program is led by Boston-based Rapport Therapeutics, a neuroscience biotech developing precision small-molecule medicines. In its official announcement, the company reported that RAP-219 met its primary endpoint—reducing objective “long episodes” captured by implanted neurostimulator devices—and was generally well tolerated. Rapport says it plans two Phase 3 trials following regulatory consultation. You can read the sponsor’s details in the Rapport Therapeutics press release.
Academic leadership matters here, too. The multicenter study includes investigators from NYU Langone Health, where epilepsy specialist Jacqueline French, MD has emphasized the trial’s novel use of continuous electrophysiology from responsive neurostimulation (RNS) systems to anchor endpoints. Coverage in NeurologyLive highlights both the magnitude of the seizure reductions and the objective biomarker approach—an advance that helps translate lab insights into clinical decisions.
Finally, transparency on the protocol and sites comes via public trial registries. The study—NCT06377930—is listed on CenterWatch as an open-label, proof-of-concept trial in 30 adult participants with refractory focal epilepsy, all implanted with RNS for continuous recording. Basic design elements and eligibility criteria are summarized on CenterWatch.
What makes RAP-219 different—and why that’s good news
Most anti-seizure medications act broadly on neuronal excitability, which can curb seizures but also bring sedation, cognitive fog, or motor side effects. RAP-219 was built with a more anatomically selective idea in mind: it modulates AMPA receptors through TARPγ8, a regulatory subunit that is enriched in brain regions—like the neocortex and hippocampus—where focal seizures commonly arise. That targeting is the rationale for achieving strong seizure control while potentially avoiding the “whole-brain” downsides that limit many therapies. Early signals in the trial support this: the drug reduced the study’s objective biomarker of pathologic activity (long episodes) and achieved sizable clinical seizure reductions, with mostly mild to moderate adverse events reported by the sponsor.
Beyond one drug, the study’s method is a win for patients. Using implanted RNS devices to quantify abnormal electrical bursts gives researchers real-time, objective measures that correlate with clinical seizures. That helps de-risk development and makes success (or failure) clearer earlier—potentially speeding useful medicines to people who need them.
Where this could lead next
For people living with uncontrolled focal seizures, any sustained drop in frequency can be life-changing—protecting employment, independence, safety, and mental health. The RAP-219 data point to a credible new option if larger, controlled studies confirm both efficacy and tolerability. According to NeurologyLive, Rapport plans a formal meeting with regulators and expects to start two pivotal studies, a standard path toward potential approval if outcomes hold.
Overall, this moment is encouraging without hype: a purpose-built medicine, a thoughtful clinical design, and collaboration between a biotech sponsor and academic leaders are combining to push the frontier of epilepsy care. If the Phase 3 results echo what’s been seen so far, people with drug-resistant focal epilepsy could soon have a treatment that is both effective and precise—and that’s good news.
More Good News
-
Ghana repeals legislation that opened forest reserves to mining
In a historic win for conservation, the Parliament of Ghana has repealed L.I. 2462, effectively banning mining activities in the country’s protected forest reserves. This decision follows months of intense advocacy from a coalition of labor unions, religious groups, and environmental organizations. The repeal safeguards critical watersheds that provide drinking water to millions and protects vital habitats for endangered species. This legislative reversal marks a decisive shift toward sustainable development and restores the legal sanctity of Ghana’s natural heritage.
-
Fentanyl overdose deaths in the U.S. are now falling sharply
The United States is seeing a dramatic decline in fentanyl overdose deaths, with new data showing a drop of approximately 33% in 2024 after the crisis peaked at 76,000 deaths in 2023. Preliminary findings suggest continued double-digit reductions in 2025. This positive trend is driven by successful diplomatic efforts to cut off precursor chemicals from China, disrupting the supply chain. Simultaneously, the widespread availability of naloxone and expanded access to addiction treatment are saving lives domestically.
-
Major rewilding effort removes 100 miles of fencing across the Great Plains of Montana
Led by the American Prairie Reserve, this initiative relies on volunteers to clear abandoned barbed wire that endangers wildlife and fragments habitat. The removal reopens ancient migration corridors for species like pronghorn antelope and elk, allowing them to move freely across the landscape. This project restores the natural beauty of the prairie and serves as a powerful model for reconnecting fragmented ecosystems nationwide.
-
China achieves breakthrough in fusion reactor plasma density
China has achieved a major breakthrough in the quest for viable fusion power with its experimental EAST reactor in Hefei, Anhui Province. The device shattered a world record by sustaining plasma at 158 million degrees Fahrenheit for over 17 minutes. This engineering feat proves that the extreme conditions needed for fusion can be stabilized for long durations. The breakthrough is a critical step in the global effort to develop abundant, safe, carbon-free energy supplies and combat climate change.
-
The Faroe Islands legalizes abortion
In a landmark victory for reproductive freedom, the Faroe Islands parliament has voted to legalize abortion, ending one of Europe’s most restrictive bans. The new law allows for abortion on demand up to the 12th week of pregnancy, aligning the archipelago with its Nordic neighbors. This historic change removes the need for women to travel to Denmark for care, ensuring access to essential medical services at home. The decision is a triumph for grassroots activists who campaigned for years to modernize the nation’s healthcare laws.